[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Angiogenex Inc (AGGX)

Angiogenex Inc (AGGX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Angiogenex Inc

Sector:

N/A

INDUSTRY GROUPING:

N/A

Description:

AngioGenex, Inc. was incorporated in the State of Nevada on April 2, 1999. It is a biopharmaceutical company, focuses on the development of products that are used in the treatment, diagnosis, and prognosis of cancer. The company primarily engages in the research to develop anti-cancer strategies using the field of antiangiogenesis. The company's development programs focus on the discovery and development of orally active anti-cancer drugs that act by modulating the action of the Id (inhibitor of differentiation) proteins; the measurement of Id proteins in tumors and blood to create products for the diagnosis and prognosis of cancer; generating proof-of-concept data in relevant preclinical models to establish that modulation of Id genes and proteins is useful to treat non-oncologic diseases; and collaborating in respect to treatments of diseases in which blood vessel proliferation is desirable. The company has a worldwide license for two patent applications relating to a method for modulating tumor growth and metastasis of tumor cells based on the Id technology and Id knockout mice useful for testing and developing useful products for the treatment, diagnosis, and prognosis of cancer from the Memorial Sloan Kettering Cancer Center.

Key Statistics

Overview:

Financials:

Annual Sales, $ 0 K
Annual Net Income, $ 0 K

Growth:

1-Year Return 0.00%
3-Year Return 0.00%
5-Year Return 0.00%

Per-Share Information:

Next Earnings Date N/A
Dividend Payout Ratio 0.00%

AGGX Ratios

Ratio
Price/Earnings ttm N/A
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % N/A
Return-on-Assets % N/A
Profit Margin % 0.00%
Debt/Equity N/A
Price/Sales N/A
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share N/A
Interest Coverage N/A
60-Month Beta N/A
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.